دورية أكاديمية

Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer.

التفاصيل البيبلوغرافية
العنوان: Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer.
المؤلفون: Schettini, F, Nucera, S, Brasó-Maristany, F, De Santo, I, Pascual, T, Bergamino, M, Galván, P, Conte, B, Seguí, E, García Fructuoso, I, Gómez Bravo, R, Rivera, P, Rodríguez, A B, Martínez-Sáez, O, Ganau, S, Sanfeliu, E, González-Farre, B, Vidal Losada, M J, Adamo, B, Cebrecos, I, Mension, E, Oses, G, Jares, P, Vidal-Sicart, S, Mollà, M, Muñoz, M, Prat, A
المصدر: ESMO Open ; ISSN:2059-7029 ; Volume:9 ; Issue:7
بيانات النشر: Elsevier Science
سنة النشر: 2024
المجموعة: PubMed Central (PMC)
مصطلحات موضوعية: HER2 dynamics, HER2-low, hormone receptor-positive, neoadjuvant chemotherapy, neoadjuvant endocrine therapy
الوصف: The characterization and comparison of gene expression and intrinsic subtype (IS) changes induced by neoadjuvant chemotherapy (NACT) and endocrine therapy in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2)-low versus HR+/HER2-0 breast cancer (BC) has not been conducted so far. Most evidence on the association of HER2 status with pathologic responses and prognosis in HR+/HER2-negative BC is controversial and restricted to NACT-treated disease. Similarly, a temporal heterogeneity in HER2 status has been described only with NACT.
نوع الوثيقة: article in journal/newspaper
اللغة: English
العلاقة: https://doi.org/10.1016/j.esmoop.2024.103619Test; https://pubmed.ncbi.nlm.nih.gov/38943737Test
DOI: 10.1016/j.esmoop.2024.103619
الإتاحة: https://doi.org/10.1016/j.esmoop.2024.103619Test
https://pubmed.ncbi.nlm.nih.gov/38943737Test
حقوق: Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.
رقم الانضمام: edsbas.8C4DAC83
قاعدة البيانات: BASE